After Oppenheimer and Merrill Lynch gave Vertex Pharmaceuticals (NASDAQ: VRTX) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Cory Kasimov maintained a Buy rating on Vertex Pharmaceuticals yesterday. The company’s shares closed last Tuesday at $230.55.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.5% and a 57.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vertex Pharmaceuticals with a $281.67 average price target, which is a 20.0% upside from current levels. In a report issued on December 29, Oppenheimer also maintained a Buy rating on the stock with a $305.00 price target.
See today’s analyst top recommended stocks >>
Vertex Pharmaceuticals’ market cap is currently $61.02B and has a P/E ratio of 23.20. The company has a Price to Book ratio of 9.16.
Based on the recent corporate insider activity of 130 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.